| Heart failure management: the present and the future. | |
| | |
MedLine Citation:
|
PMID: 19203220 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Clinical heart failure has been defined for a long time as a clinical syndrome with symptoms and signs including shortness of breath, cyanosis, ascites, and edema. However, in recent years, with the thought of promoting early diagnosis and heart-failure prevention, the concept of heart failure has often been defined simply as a subject with severe LV dysfunction and a dilated left ventricle, or by some, defined by evidence of increased circulating levels of molecular markers of cardiac dysfunction, such as ANP and BNP. Heart failure has been considered an irreversible clinical end point. Current medical management for heart failure only relieves symptoms, slows deterioration, and prolongs life modestly. However, in the recent years, rejuvenation of the failing myocardium began to seem possible as the accumulating preclinical studies demonstrated that rejuvenating the myocardium at the molecular and cellular level can be achieved by gene therapy or stem cell transplantation. Here, we review selected novel modalities that have been shown in preclinical studies to exert beneficial effects in animal models of severe LV dysfunction and seem to have the potential to make an impact in the clinical practice of heart-failure management. |
| | |
Authors:
|
Mohammad N Jameel; Jianyi Zhang |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Antioxidants & redox signaling Volume: 11 ISSN: 1557-7716 ISO Abbreviation: Antioxid. Redox Signal. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-12-01 Completed Date: 2010-02-18 Revised Date: 2011-03-14 |
Medline Journal Info:
|
Nlm Unique ID: 100888899 Medline TA: Antioxid Redox Signal Country: United States |
Other Details:
|
Languages: eng Pagination: 1989-2010 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, University of Minnesota, Minneapolis, Minnesota 55455, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Atrial Natriuretic Factor / blood Gene Therapy Heart Failure / blood, drug therapy, therapy* Humans Natriuretic Peptide, Brain / blood |
| Grant Support | |
ID/Acronym/Agency:
|
HL 67828/HL/NHLBI NIH HHS; HL50470/HL/NHLBI NIH HHS; HL61353/HL/NHLBI NIH HHS; R01 HL050470-13/HL/NHLBI NIH HHS; R01 HL061353-05/HL/NHLBI NIH HHS; R01 HL067828-07/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
114471-18-0/Natriuretic Peptide, Brain; 85637-73-6/Atrial Natriuretic Factor |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Enyne Metathesis/Br??nsted Acid-Promoted Heterocyclization.
Next Document: CARDIAC REPAIR WITH ADULT BONE MARROW-DERIVED CELLS: THE CLINICAL EVIDENCE.